Phaseline

Companies › Tessera Therapeutics

Tessera Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Mar 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TSRA-196
In-vivo genome editing via lipid nanoparticles to increase alpha-1 antitrypsin expression
SERPINA1Phase 1Alpha-1 Antitrypsin Deficiency (AATD)Mar 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07227207TSRA-196Phase 1Alpha-1 Antitrypsin Deficiency (AATD)Metabolic and endocrineMar 2029

Targets

SERPINA1 (1)

Companies with the same targets

Krystal Biotech Takeda Wave Life Sciences USA Beam Therapeutics Grifols Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.